French drugmaker gains access to Covid shot and other tech Sanofi also takes a small stake in Maryland-based company -rte-company state="{"_id":"0000018f-638a-d4b6 ...
opens new tab on Friday said it had struck a licensing deal worth ... well as royalties. Sanofi, one of the world's largest vaccine makers, will gain a license to co-sell Novavax's vaccine in ...
The vaccine maker said overnight that it has reached a licensing agreement ... As part of the deal, Sanofi will take a minority equity investment in Novavax. Write to Dean Seal at dean.seal@ ...
Licensing agreement includes commercializing a combined Covid-19 and flu shot Sanofi and Novavax Inc. signed a licensing agreement that includes commercializing a combined Covid-19 and flu shot.
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi (SNY, FR:SAN). Novavax shares were up 133% in recent trading at $10.11.
As part of the deal, Sanofi (SNY) will receive a license to co-commercialize Novavax's (NVAX) COVID-19 vaccine worldwide and a sole license to use the vaccine in combination with its flu vaccines.
after the COVID-19 vaccine maker struck a licensing deal with Sanofi (SASY.PA) , opens new tab. Under a deal signed on May 10, the French drugmaker will take a 4.9% stake in Novavax for $70 ...
The co-exclusive licensing agreement between the two pharmaceutical companies includes co-commercializing Novavax's COVID-19 vaccine and developing a combination vaccine for the flu and COVID-19.
Novavax said the licensing agreement allows ... will co-market Novavax's Covid vaccine in most countries starting in 2025. The deal also allows Sanofi to use Novavax's Covid shot and flagship ...
Under the licensing agreement, Sanofi will pay Novavax $500 million upfront with up to $700 million in milestone payments, making the deal worth up to $1.2 billion. The agreement also gives Sanofi ...